TOP - May 2015, Vol 8, No 2

Handling and disposing of oral cancer therapies can be hazardous, and certain protocols should be followed to reduce risks, according to Lisa Holle, PharmD, who spoke at the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference.
At the American Society for Blood and Marrow Transplantation’s (ASBMT) 2015 BMT Tandem Meetings, 4 studies were named the “Best Pharmacy Abstracts,” and are summarized here for our readers.
The American Society for Blood and Marrow Trans­plantation (ASBMT) Pharmacy Spe­cial Interest Group (SIG) is rapidly growing in both membership and opportunities, according to Jamie F. Shapiro, PharmD, BCOP, Clinical Pharmacy Coordinator, Stem Cell Transplant, and Chair of the ASBMT Pharmacy SIG.
According to a recent assessment of bowel dysfunction–related needs, the hardships for colorectal cancer (CRC) survivors continue long after leaving the operating room, and survivors desire more information and strategies to help cope with unexpected changes to their bowel patterns, researchers said at the 2015 Gastrointestinal Cancers Symposium held in San Francisco, CA.
“There is a very strong link between shift work and lack of sleep, and fewer hours of sleep can translate to a higher risk for obesity and disease,” according to Eva S. Schernhammer, MD, DrPH, who spoke at the recent American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research.
Adding an erythropoiesis-stimulating agent (ESA) to best supportive care failed to demonstrate noninferiority for progression-free survival (PFS) compared with best supportive care alone in patients with metastatic breast cancer, in a clinical trial known as EPO-ANE-3010 that was requested by the FDA.
  • Anti-CD19 CAR T-Cells Show Promise in B-Cell Cancer
  • Lenvatinib Prolongs Progression-Free Survival in Advanced Thyroid Cancer
  • Ruxolitinib More Effective Than Standard Therapy in the Treatment of Polycythemia Vera
An investigational first-in-class anticancer quinolone derivative, vosaroxin, extended median overall survival (OS) when used with cytarabine (Cytosar-U) in a phase 3 clinical trial of patients with relapsed or refractory acute myeloid leukemia (AML), although the difference was not significant.
We interviewed Hi (Jenny) An, PharmD, Pharmacy Supervisor at the Virginia K. Crosson Cancer Center, St. Joseph’s Healthcare System, in Fullerton, CA, about her unique experiences in oncology pharmacy.
Disease progression is slower and overall survival (OS) is greater in patients with chronic myeloid leukemia (CML) who are being monitored for their response to tyrosine kinase inhibitor (TKI) therapy and show good adherence. However, few clinicians monitor response and adherence to oral TKI treatment in patients with CML.
Page 1 of 2
Results 1 - 10 of 20